Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News GRI Bio Inc GRI

Healthcare Biotechnology
GRI Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing therapies that target serious diseases associated with dysregulated immune responses leading to inflammatory, fibrotic, and autoimmune disorders. Its therapies are designed to target the activity of Natural Killer T (NKT) cells, which are key regulators earlier in... see more

Recent & Breaking News (NDAQ:GRI)

Vallon Pharmaceuticals Presents Data from Adult Stimulant Abuse Pattern Survey at the American Academy of Child and Adolescent Psychiatry (AACAP) 68th Annual Meeting

GlobeNewswire November 1, 2021

Vallon Pharmaceuticals Provides Update on Recent Pipeline and Corporate Advancements

GlobeNewswire October 12, 2021

Vallon Pharmaceuticals Announces Formation of Scientific Advisory Board

GlobeNewswire September 14, 2021

Vallon Pharmaceuticals to Present at the Q3 Virtual Investor Summit

GlobeNewswire August 11, 2021

Vallon Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update

GlobeNewswire August 10, 2021

Vallon Pharmaceuticals Announces Issuance of New European Patent Covering Method of Use and Composition of Matter for ADAIR

GlobeNewswire July 13, 2021

Vallon Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update

GlobeNewswire May 13, 2021

Vallon Pharmaceuticals Appoints Leanne Kelly as Chief Financial Officer

GlobeNewswire May 11, 2021

Vallon Pharmaceuticals to Present at the Q2 Virtual Investor Summit

GlobeNewswire May 7, 2021

Vallon Pharmaceuticals to Participate at the 4th Annual Neuroscience Innovation Forum

GlobeNewswire April 26, 2021

Vallon Pharmaceuticals Continues Advancement of Pivotal Study in Lead Development Program, ADAIR, Toward Potential Approval

GlobeNewswire April 13, 2021

Vallon Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Corporate Update

GlobeNewswire March 29, 2021

Vallon Pharmaceuticals to Present at the H.C. Wainwright Global Life Sciences Conference

GlobeNewswire March 3, 2021

Vallon Pharmaceuticals Appoints Marella Thorell to Board of Directors

GlobeNewswire February 23, 2021

Vallon Pharmaceuticals Announces Closing of Initial Public Offering

GlobeNewswire February 12, 2021

Vallon Pharmaceuticals Announces Pricing of Initial Public Offering

GlobeNewswire February 9, 2021